Kairos Pharma Ltd (KAPA)

Form 8-K - Current report

Form 8-K - Current report

Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders

Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, provides a...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

Kairos Pharma Receives GHP Magazine’s Healthcare & Pharmaceutical Award

Company selected for the Leaders in Drug Resistance Development award Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI

Los Angeles, California--(Newsfile Corp. - May 13, 2026) - Kairos Pharma, Ltd. (NYSE American: KAPA) announced today that it will be participating...

Form PRE 14A - Other preliminary proxy statements

Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announces that...

Kairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare Innovation

Company selected as an Emerald honoree for Innovator of Biotech Solutions Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]